11/7/2022 0 Comments Marshall jmp 1Having set up the session the night before, producer Neil Dorfsman found an SM57 mic pointing at the floor when he arrived. The firm's revenue was up 33.9% compared to the same quarter last year.Mark Knopfler’s guitar sound on Money For Nothing was actually an accident. Blueprint Medicines had a negative net margin of 304.41% and a negative return on equity of 45.89%. The firm had revenue of $36.55 million during the quarter, compared to analysts' expectations of $37.61 million. The biotechnology company reported ($2.68) EPS for the quarter, missing the consensus estimate of ($2.23) by ($0.45). Blueprint Medicines has a twelve month low of $43.46 and a twelve month high of $117.86.īlueprint Medicines ( NASDAQ:BPMC - Get Rating) last issued its quarterly earnings results on Tuesday, August 2nd. The firm has a market cap of $4.63 billion, a P/E ratio of -6.55 and a beta of 0.78. The company has a 50 day moving average of $62.53 and a 200-day moving average of $60.57. Shares of NASDAQ:BPMC opened at $77.70 on Friday. According to data from, the company has an average rating of "Moderate Buy" and an average price target of $92.19. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. Finally, Stifel Nicolaus increased their price objective on shares of Blueprint Medicines from $93.00 to $100.00 and gave the stock a "buy" rating in a research note on Thursday, August 18th. Credit Suisse Group upped their price target on shares of Blueprint Medicines from $80.00 to $90.00 in a research note on Wednesday. Piper Sandler dropped their price objective on shares of Blueprint Medicines from $65.00 to $59.00 in a research report on Tuesday, August 2nd. Oppenheimer increased their target price on shares of Blueprint Medicines from $80.00 to $90.00 and gave the stock an "outperform" rating in a report on Tuesday. The Goldman Sachs Group increased their target price on shares of Blueprint Medicines from $126.00 to $143.00 and gave the stock a "buy" rating in a research report on Wednesday, August 3rd. Morgan Stanley's price target points to a potential upside of 2.96% from the company's previous close.Ī number of other equities research analysts have also recently issued reports on the stock. The firm currently has an "equal weight" rating on the biotechnology company's stock. 7 Dividend Aristocrats to Help You Take the Bite Out of the Bearīlueprint Medicines ( NASDAQ:BPMC - Get Rating) had its price objective increased by stock analysts at Morgan Stanley from $65.00 to $80.00 in a report issued on Friday, Benzinga reports.10 Recession-Proof Stocks That Will Let You Wait Out the Bear.7 Stocks with the Pricing Power to Push Through High Inflation.7 Blue-Chip Dividend Stocks That Won’t be Impacted by Rising Interest Rates.7 Mid-Cap Stocks That Can be the Perfect Fit at Any Time.7 Stocks to Buy to Outrun Rising Interest Rates.7 Sports Betting Stocks to Buy for Their Long-Term Possibilities.7 Water Stocks to Buy as the World Dries Up.7 Solar Stocks Leading the Clean Energy Boom.7 Railroad Stocks to Keep Your Portfolio Chugging Along.7 Agricultural Stocks to Buy to Keep Your Portfolio Well Fed. MARSHALL JMP 1 CRACKERCracker Barrel: A Tasty Treat Or Bad Apple?.Mullen Automotive Is Ready To Get In Gear.Can United Natural Foods Fight Both Inflation and the Fed?.Can HCA Healthcare Weather the Normalization?.This Little Known Small Cap Is Up 139%: Is The Stock A Buy?.Blackberry Stock Declines As Results Come In Lukewarm Once Again.What Cintas Can Teach Investors About This Bear Market?.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |